TNFRSF11A and neoplasm: Ultimately, indifferent to the radiologic nature of BM or tumor type, RANKL/RANK pathway blockade is able to abrogate cancer-induced osteoclastogenesis and bone resorption, delaying and decreasing SREs [28].